uniQure N.V. (NASDAQ:QURE) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have received an average recommendation of “Moderate Buy” from the seventeen brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $42.8333.

A number of research analysts have issued reports on QURE shares. Sanford C. Bernstein cut uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $15.00 to $60.00 in a report on Monday, March 9th. Cantor Fitzgerald reissued a “neutral” rating and set a $9.00 price objective (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Finally, Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer directly owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the transaction, the insider directly owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 75,801 shares of company stock valued at $1,406,757 in the last ninety days. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Torren Management LLC bought a new position in shares of uniQure in the fourth quarter valued at about $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. IFP Advisors Inc bought a new position in shares of uniQure in the fourth quarter valued at about $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure in the fourth quarter valued at about $48,000. Finally, CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the third quarter valued at about $50,000. 78.83% of the stock is owned by institutional investors.

uniQure Stock Down 1.3%

QURE opened at $24.85 on Friday. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm’s fifty day moving average price is $19.91 and its two-hundred day moving average price is $21.87. The company has a market capitalization of $1.57 billion, a P/E ratio of -7.14 and a beta of 0.87.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, analysts anticipate that uniQure will post -3.68 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.